{
    "nct_id": "NCT04076943",
    "official_title": "A Phase 2 Open Label Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies",
    "inclusion_criteria": "1. Diagnosis of non-myeloid malignancy\n2. Anemia caused by cancer treatment (myelosuppressive chemotherapy) defined as Hb ≤10.0 grams (g)/deciliter (dL) at screening\n3. Planned concurrent treatment of cancer with chemotherapy for at least 8 additional weeks\n4. Estimated life expectancy ≥ 6 months at enrollment (Day 1)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Participants with cancer receiving chemotherapy when the anticipated outcome is cure\n2. Participants who are only receiving hormonal products, biological products, cancer immunotherapy or radiation therapy to treat/manage their cancer\n3. History of leukemia\n4. Participants who have received an RBC transfusion or erythropoietic therapy within 4 weeks of enrollment\n5. Use of any investigational drug within 8-weeks prior to treatment with roxadustat\n6. Clinically significant anemia due to other etiologies\n7. Cardiovascular risks, such as myocardial infarction, stroke, heart failure or thromboembolic event (for example, deep vein thrombosis [DVT] or pulmonary embolism) within previous 6 months of screening\n8. Clinically significant or uncontrolled ongoing autoimmune disease (for example, rheumatoid arthritis, Crohn's disease, celiac disease, etc.)\n9. Known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection",
    "miscellaneous_criteria": ""
}